Comparison of J5 vaccinates and controls for incidence, etiologic agent, clinical severity, and survival in the herd following naturally occurring cases of clinical mastitis

Journal of Dairy Science

Volumn 90, Issue 9, 2007, Pages 4282-4288

  Wilson, D J ^a   Grohn, Y T ^b   Bennett, G J ^b   Gonzalez R N ^b   Schukken, Y H ^b   Spatz, J ^c  

^a UTAH STATE UNIVERSITY   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c Animal Health Centre   (New Zealand)

Author keywords

Bovine mastitis; Clinical mastitis; Dairy cattle; Immunology

Indexed keywords

ANIMALIA; BACTERIA (MICROORGANISMS); BOS; BOVINAE; KLEBSIELLA;

LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE, E COLI J5; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL DISEASE; ARTICLE; CATTLE; CATTLE DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENTEROBACTER INFECTION; FEMALE; IMMUNOLOGY; LACTATION; MICROBIOLOGY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ANIMALS; CATTLE; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI INFECTIONS; FEMALE; KLEBSIELLA INFECTIONS; LACTATION; LIPOPOLYSACCHARIDES; MASTITIS, BOVINE; PREGNANCY; VACCINATION;

EID: 34848907805     PISSN: 00220302     EISSN: 15253198     Source Type: Journal    
DOI: 10.3168/jds.2007-0160     Document Type: Article

References (12)

1. Cross, A. S., S. M. Opal, H. S. Warren, J. E. Palardy, K. Glaser, N. A. Parejo, and A. K. Bhattacharjee. 2001. Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. J. Infect. Dis. 183:1079-1086.
2. Cullor, J. S. 1991. The Escherichia coli J5 vaccine: Investigating a new tool to combat mastitis. Vet. Med. (Praha) 86:836-844.
3. Fleming, T. R., and D. Y. Lin. 2000. Survival analysis in clinical trials: Past developments and future directions. Biometrics 56:971-983.
4. González, R., J. Cullor, D. Jasper, T. Farver, R. Bushnell, and M. Oliver. 1989. Prevention of clinical coliform mastitis in dairy cows by a mutant Escherichia coli vaccine. Can. J. Vet. Res. 53:301-305.
5. González, R. N., D. J. Wilson, H. O. Mohammed, P. M. Sears, A. L. Rivas, and S. G. Campbell. 1996. A placebo-controlled trial of an Escherichia coli J5 bacterin and the ribotyping-based assessment of coliform bacteria diversity on a dairy farm. Pages 277-280 in Proc. 19th World Buiatrics Congr., Edinburgh, Scotland. Br. Cattle Vet. Assoc., Frampton-on-Severn, UK.
6. Hogan, J. S., R. N. González, R. J. Harmon, S. C. Nickerson, S. P. Oliver, J. W. Pankey, and K. L. Smith. 1999. Pages 85-111 in Laboratory Handbook on Bovine Mastitis. NMC Inc., Madison, WI.
7. Hogan, J. S., K. L. Smith, D. A. Todhunter, and P. S. Schoenberger. 1992. Field trial to determine efficacy of an Escherichia coli J5 mastitis vaccine. J. Dairy Sci. 75:78-84.
8. Jackson, E., and J. Bramley. 1983. Coliform mastitis. In Pract. 5:135-146.
9. McClure, A., E. Christopher, W. Wolff, W. H. Fales, G. F. Krause, and J. Miramonti. 1994. Effect of Re-17 mutant Salmonella Typhimurium bacterin toxoid on clinical coliform mastitis. J. Dairy Sci. 77:2272-2280.
10. Scott, H. M., J. M. Sargeant, M. J. Ireland, K. E. Leslie, K. D. Lissemore, D. F. Kelton, and B. A. Mallard. 1996. Efficacy of an Re17 mutant Salmonella Typhimurium core antigen vaccine under field conditions. Pages 281-284 in Proc. 19th World Buiatrics Congr., Edinburgh, Scotland. Br. Cattle Vet. Assoc., Framptonon-Severn, UK.
11. Wenz, J. R., G. M. Barrington, F. B. Garry, K. D. McSweeney, R. P. Dinsmore, G. Goodell, and R. J. Callan. 2001. Bacteremia associated with naturally occurring acute coliform mastitis in dairy cows. J. Am. Vet. Med. Assoc. 219:976-981.
12. Wilson, D. J., R. N. González, and H. H. Das. 1997. Bovine mastitis pathogens in New York and Pennsylvania: Prevalence and effects on somatic cell count and milk production. J. Dairy Sci. 80:2592-2598.